Back to top
more

Celularity (CELU)

(Delayed Data from NSDQ)

$3.55 USD

3.55
7,570,559

+0.46 (14.89%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $3.56 +0.01 (0.28%) 6:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Investors Heavily Search Celularity, Inc. (CELU): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Celularity, Inc. (CELU) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs

by Zacks Equity Research

Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%. Shares fall.

Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View

by Zacks Equity Research

Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.

Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22

by Zacks Equity Research

Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.

After Plunging -38.63% in 4 Weeks, Here's Why the Trend Might Reverse for Celularity, Inc. (CELU)

by Zacks Equity Research

Celularity, Inc. (CELU) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Roche's (RHHBY) Cancer Drug Glofitamab Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.

Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes

by Zacks Equity Research

Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.

TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug

by Zacks Equity Research

The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023. Stock up.

AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers

by Zacks Equity Research

The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.

Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012

by Zacks Equity Research

The FDA accepts Kala Pharmaceuticals' (KALA) investigational new drug application for pipeline candidate KPI-012 for treating persistent corneal epithelial defect. Stock up.

ACER Down Despite FDA Nod for Urea Cycle Disorders Drug

by Zacks Equity Research

The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.

Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Celularity, Inc. (CELU)

by Zacks Equity Research

Celularity, Inc. (CELU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

All You Need to Know About Celularity, Inc. (CELU) Rating Upgrade to Strong Buy

by Zacks Equity Research

Celularity, Inc. (CELU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.

BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing

by Zacks Equity Research

The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.

Down 35.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Celularity, Inc. (CELU)

by Zacks Equity Research

Celularity, Inc. (CELU) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Ardelyx (ARDX) Up 41% After FDA Committee Endorses CKD Drug

by Zacks Equity Research

The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.

4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why

by Zacks Equity Research

4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.

Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down

by Zacks Equity Research

Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.

Celularity, Inc. (CELU) Q3 Earnings Beat Estimates

by Zacks Equity Research

Celularity, Inc. (CELU) delivered earnings and revenue surprises of 111.54% and 21.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of -33.33% and 26.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Celularity, Inc. (CELU) Q2 Earnings Beat Estimates

by Zacks Equity Research

Celularity, Inc. (CELU) delivered earnings and revenue surprises of 111.54% and 32.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of -24.32% and 48.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -10% and 7.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amarin (AMRN) Q4 Earnings Top, Sales Hurt by Vascepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.